AI interpretation based on checked source excerpts. Issuer assertions and evidence limitations remain explicit.
Policy quality-scores-2: six equally weighted categories. The overall score requires full coverage. Missing inputs are not zero. Qualitative grades are sourced interpretations, not probabilities. 6/6 · 18/10/2026
Moat63
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
structural advantage · 3/4 · Actual multi-year purchase commitments tied to instrument provision establish economic switching friction, corroborated by high reported retention. The advantage is stronger than a strategy claim, although competitive comparisons are absent.
durability · 2/4 · Commitments protect demand over multiple years, and installed-base growth reinforces recurring opportunities. Evidence does not establish post-contract retention or exceptional durability, while hospital consolidation provides a credible route around the relationship.
customer dependency · 3/4 · High-nineties retention in key CAG Diagnostics, increased testing by existing customers and long-term consumable commitments demonstrate repeat demand and dependency. The retention figure is issuer-reported and lacks cohort methodology.
erosion resilience · 2/4 · Higher recurring prices and volumes and continued organic growth indicate current resilience. Corporate purchasing concentration and instrument pricing concessions limit confidence across a longer competitive cycle; the consolidation risks are prospective rather than demonstrated losses.
Pricing power69
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
realized pricing · 3/4 · First-half results attribute recurring diagnostics and software-related growth to higher realized prices alongside higher volumes. This demonstrates pricing power in recurring offerings, tempered by lower instrument revenue from program pricing and absent price-rate detail.
retention · 3/4 · The disclosed high-nineties key CAG retention and subsequent increased existing-customer testing support repeat demand alongside realized-price gains. This uses direct issuer retention disclosure and indirect operating corroboration, not an invented renewal rate.
margin resilience · 3/4 · Comparable operating margin increased from 30.5% to 31.4% in 2025; first-half 2026 gross and operating margins also improved. Together with observed price and volume gains, these results support resilience, although they do not isolate pricing from mix, productivity or other effects.
contractual freedom · 2/4 · Accounting for committed purchases explicitly includes expected price adjustments, supporting some pricing flexibility within customer arrangements. Minimum-purchase contracts and incentives qualify that flexibility; the passages do not establish unrestricted repricing rights or escalation terms.
Predictability98
Five consecutive annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.
- Nondeclining revenue years (%)
- 100.00
- Revenue growth volatility (pp)
- 2.17
- Positive FCF years (%)
- 100.00
- FCF margin volatility (pp)
- 4.26
Financial strength84
Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, or reported pretax profit plus reported interest expense when operating income is unavailable. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.
- debtFcfGrade
- 100.00
- netDebtEbitGrade
- 96.03
- interestCoverageGrade
- 100.00
- currentRatioGrade
- 38.45
- Debt / FCF (x)
- 0.43
- Net debt / operating income (x)
- 0.20
- Interest coverage (x)
- 35.01
- Current ratio (x)
- 1.23
Capital allocation99
Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income or, if unavailable, EBIT calculated from reported pretax profit plus reported interest expense; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. Nonpositive invested capital has no defined return and remains unavailable. Does not establish acquisition quality or buyback timing.
- 3-year pre-tax operating return (%)
- 68.88
- 3-year average dilution (%)
- -1.29
- 3-year average SBC / revenue (%)
- 1.52
- cashConversionGrade
- 94.47
Management56
Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.
capital discipline · 2/4 · Operating cash generation comfortably covered property and equipment spending in 2025 and first-half 2026. However, repurchases exceeded operating cash flow less that spending in both periods, alongside revolving borrowings. This supports a mixed assessment; repurchase value creation and acquisition returns are unproven.
incentive alignment · 2/4 · Actual compensation includes annual performance bonuses and long-term equity incentives, with achieved 2025 bonus results disclosed. Multi-year PSU metrics support alignment, but broad adjustment discretion, undisclosed end-period targets and missing executive ownership evidence limit confidence. Outstanding PSU awards are not treated as vested outcomes.
execution · 3/4 · Instrument placements and installed-base expansion, first-half 2026 organic revenue growth of 10.0%, rising operating profit and stronger cash generation demonstrate execution. This assessment combines issuer-reported operational achievements with financial outcomes; it does not assume future launches or attribute every improvement to management.
governance · 2/4 · Entirely independent standing committees provide substantive oversight structure. The March proxy also discloses a classified board. Declassification and special-meeting amendments remained conditional in that disclosure, and the supplied passages do not verify their eventual implementation.
Evidence
Reagent rentals Instruments being placed at customer sites at little or no cost in exchange for a long-term customer commitment to purchase instrument consumables.
Glossary: reagent rentals · Filed 20/02/2026
Many of our customer commitment arrangements provide customers with free or discounted instruments or systems upon entering into multi-year arrangements to purchase minimum annual amounts of products and services.
Revenue recognition: free or discounted instruments and systems · Filed 04/08/2026
+Customer retention in the high nineties within our key CAG Diagnostics business.
2025 business execution: CAG Diagnostics customer retention · Filed 27/03/2026
Volume growth was supported by high customer retention rates with increased testing by existing customers, including our expanded menu of available tests, as well as new customer additions.
Six-month revenue discussion: retention and existing-customer testing · Filed 04/08/2026
Total Company Revenue. The increase in revenue primarily reflected growth in CAG Diagnostics recurring revenue, including benefits from higher volumes and higher realized prices.
Six-month revenue discussion: recurring diagnostics volumes and realized prices · Filed 04/08/2026
Notable 2025 business execution highlights include: +More than 22,000 premium instrument placements, including over 6,000 IDEXX inVue Dx™ cellular analyzers, driving 12% growth in our premium instrument installed base.
2025 business execution: instrument placements and installed-base growth · Filed 27/03/2026
Higher volumes and realized price gains in recurring veterinary software, services, and diagnostic imaging also contributed to revenue growth.
Six-month revenue discussion: recurring software, services and imaging · Filed 04/08/2026
While we have strong supplier relationships with several corporate hospital groups and buying consortiums, decisions by larger corporate owners and buying consortiums to shift their purchases to a competitor would have a negative impact on our results of operations from the loss of future business.
Risk factors: corporate hospital groups and buying consortiums · Filed 20/02/2026
Any hospitals acquired by these companies generally attempt to shift all or a large portion of their testing to the reference laboratories operated by these companies, and may attempt to shift their point-of-care diagnostic testing, as well, and there can be no assurance that hospitals that otherwise become affiliated with these companies would not shift all or a portion of their diagnostic testing.
Risk factors: acquired hospitals shifting diagnostic testing · Filed 20/02/2026
Lower instrument revenue was primarily due to program effects on pricing.
Six-month revenue discussion: instrument program pricing · Filed 04/08/2026
Any price increases we may impose may lead to declines in sales volume or loss of business, if competitors do not similarly adjust their prices, or customers refuse to purchase at the higher prices.
Effects of inflation: potential customer response to price increases · Filed 04/08/2026
We allocate total consideration, including future committed purchases and expected price adjustments, based on relative standalone selling prices to identified performance obligations and recognize instrument revenue and cost at the time of installation and customer acceptance in advance of billing the customer, which is also when the customer obtains control of the instrument based on legal title transfer.
Revenue recognition: committed purchases and expected price adjustments · Filed 04/08/2026
39 The following table presents our consolidated Company results of operations: For the Six Months Ended June 30, Change Total Company - Results of Operations (dollars in thousands) 2026 Percent of Revenue 2025 Percent of Revenue Amount Percentage Revenues $ 2,357,405 $ 2,107,884 $ 249,521 11.8 % Cost of revenue 855,579 789,773 65,806 8.3 % Gross profit 1,501,826 63.7 % 1,318,111 62.5 % 183,715 13.9 % Operating expenses: Sales and marketing 346,527 14.7 % 317,330 15.1 % 29,197 9.2 % General and administrative 235,930 10.0 % 190,242 9.0 % 45,688 24.0 % Research and development 131,217 5.6 % 120,959 5.7 % 10,258 8.5 % Total operating expenses 713,674 30.3 % 628,531 29.8 % 85,143 13.5 % Income from operations $ 788,152 33.4 % $ 689,580 32.7 % $ 98,572 14.3 % Gross Profit.
Six-month consolidated results: gross and operating margins · Filed 04/08/2026
IDEXX 2026 PROXY STATEMENT A-3 + + + APPENDIX A The reconciliation of this non-GAAP financial measure is as follows: Dollar amounts in thousands For the Year Ended December 31, 2025 For the Year Ended December 31, 2024 Year-over-Year Change (basis points)(1) Income from operations $1,360,031 $1,128,337 Operating margin and margin gain 31.6 % 29.0 % 270 bps Less: comparability adjustments Change from currency 10,213 — Now-concluded litigation matter 8,600 (61,500) Comparable income from operations $1,341,218 $1,189,837 Comparable operating margin and margin gain(1) 31.4 % 30.5 % 90 bps 1.Amounts presented may not recalculate due to rounding.
Appendix A: 2025 comparable operating margin reconciliation · Filed 27/03/2026
AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) For the Years Ended December 31, 2025 2024 2023 Cash Flows from Operating Activities: Net income $ 1,059,464 $ 887,867 $ 845,042 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 145,183 129,936 114,908 Provision for uncollectible accounts 8,429 6,867 5,552 Deferred income taxes 131,204 (24,194) (48,306) Share-based compensation expense 60,013 60,295 59,739 Other 5,026 1,468 2,004 Changes in assets and liabilities: Accounts receivable (68,722) (28,280) (53,871) Inventories (789) (28,001) (28,651) Accounts payable (8,573) 8,086 (557) Deferred revenue 6,929 (4,378) (3,032) Other assets and liabilities (156,359) (80,665) 13,682 Net cash provided by operating activities 1,181,805 929,001 906,510 Cash Flows from Investing Activities: Purchases of property and equipment (124,676) (120,922) (133,631) Acquisitions of intangible assets (13,550) (10,000) — Equity investments (756) (1,004) — Acquisitions of businesses, net of cash acquired — (76,694) — Proceeds from net investment hedges 2,743 1,558 8,377 Net cash used by investing activities (136,239) (207,062) (125,254) Cash Flows from Financing Activities: Borrowings (payments) on revolving credit facility, net 148,000 — (329,000) Payments of senior notes (178,385) (75,000) (75,000) Borrowings on term loan 250,000 — — Payments of term loan (250,000) — — Debt issuance costs (3,738) — — Repurchases of common stock (1,216,964) (837,034) (71,920) Proceeds from exercises of stock options and employee stock purchase plans 93,362 44,492 47,034 Payments of acquisition-related contingent consideration and holdbacks — — (3,135) Shares withheld for statutory tax withholding payments on restricted stock (7,239) (10,531) (9,975) Net cash used by financing activities (1,164,964) (878,073) (441,996) Net effect of changes in exchange rates on cash 11,202 (9,532) 2,126 Net increase (decrease) in cash and cash equivalents (108,196) (165,666) 341,386 Cash and cash equivalents at beginning of period 288,266 453,932 112,546 Cash and cash equivalents at end of period $ 180,070 $ 288,266 $ 453,932 The accompanying notes are an integral part of these consolidated financial statements.
Consolidated cash flows: 2023–2025 · Filed 20/02/2026
AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (Unaudited) For the Six Months Ended June 30, 2026 2025 Cash Flows from Operating Activities: Net income $ 616,858 $ 536,666 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 78,734 69,835 Impairment charge 5,000 — Provision for credit losses 6,274 4,360 Deferred income taxes 20,428 6,427 Share-based compensation expense 32,428 29,469 Other 376 1,491 Changes in assets and liabilities: Accounts receivable (82,844) (74,889) Inventories (1,787) (4,081) Other assets and liabilities (66,538) (133,460) Accounts payable 4,481 (12,113) Net cash provided by operating activities 613,410 423,705 Cash Flows from Investing Activities: Purchases of property and equipment (56,630) (64,128) Acquisition of intangible assets (3,692) — Equity investments (799) — Proceeds from net investment hedges 2,081 890 Net cash used by investing activities (59,040) (63,238) Cash Flows from Financing Activities: Borrowings (payments) on revolving credit facility, net 121,000 329,000 Payments of senior notes — (103,386) Repurchases of common stock, including excise tax settlements (697,840) (738,995) Proceeds from exercises of stock options and employee stock purchase plans 51,074 24,523 Shares withheld for statutory tax withholding payments on restricted stock (10,853) (7,094) Net cash used by financing activities (536,619) (495,952) Net effect of changes in exchange rates on cash (888) 11,813 Net increase (decrease) in cash and cash equivalents 16,863 (123,672) Cash and cash equivalents at beginning of period 180,070 288,266 Cash and cash equivalents at end of period $ 196,933 $ 164,594 Supplemental Cash Flow Information: Unpaid property and equipment, reflected in accounts payable and accrued liabilities $ 9,724 $ 8,460 The accompanying notes are an integral part of these condensed consolidated financial statements.
Condensed consolidated cash flows: first half of 2026 · Filed 04/08/2026
Our Executive Compensation Program Our executive compensation program consists of three key elements: base salary, annual performance-based cash bonus and equity-based long-term incentives.
Executive compensation: program elements · Filed 27/03/2026
2.The average annual comparable operating profit growth is determined by averaging the percentage change in our operating profit year over year during each of the three years included in the performance period, in each case adjusted to eliminate, as applicable, (i) the effects of foreign currency exchange rates and (ii) the effects of certain discrete items, including, but not limited to, restructuring charges, debt finance costs, acquisition purchase accounting adjustments, acquisition-related transaction costs and integration expenses, adjustments to finalized pre-acquisition contingencies, litigation-related expenses and payments, gains and losses on the disposition of assets or discontinued operations, non-cash writedowns or other unusual, non-recurring or extraordinary items, or otherwise in the discretion of the Compensation and Talent Committee.
Executive compensation: three-year operating profit metric and adjustments · Filed 27/03/2026
Information regarding the target, threshold, and maximum goals applicable to the average annual organic revenue growth and average annual comparable operating profit growth metrics applicable to the 2025 PSU awards, as well as performance against those metrics, will be disclosed at the end of the three-year performance period.
Executive compensation: 2025 PSU performance-period disclosure · Filed 27/03/2026
The operating profit achieved result of $1,320.6 million under our 2025 annual performance-based cash bonus plan, compared to our GAAP operating profit of $1,360.0 million, reflects a $(31.9) million adjustment to eliminate foreign currency exchange rate effects, an adjustment of $(8.6) million related to an accrual for a now-concluded litigation matter, and an aggregate adjustment of $1.1 million for other discrete items.
Appendix A: achieved results under the 2025 cash bonus plan · Filed 27/03/2026
Each Committee is composed entirely of independent Directors as determined under Nasdaq rules and acts pursuant to a written charter that is approved by the Board and reviewed annually by the applicable Committee, the Governance and Corporate Responsibility Committee and the Board.
Corporate governance: independent standing committees · Filed 27/03/2026
18 IDEXX 2026 PROXY STATEMENT Proposal One Election of Directors Our Board is divided into three classes, and members of each class hold office for three-year terms as set forth below: +Class I Directors—currently four Directors whose terms expire at the 2027 Annual Meeting; +Class II Directors—currently three Directors whose terms expire at the 2026 Annual Meeting; and +Class III Directors—currently four Directors whose terms expire at the 2028 Annual Meeting.
Election of directors: classified board structure · Filed 27/03/2026
Implementation of the Amendments If both this Proposal Four and Proposal Five are approved by shareholders, then promptly following the 2026 Annual Meeting, we intend to file with the Delaware Secretary of State a Certificate of Amendment to our Certificate of Incorporation, which would be effective upon filing, that implements all the amendments contemplated by both proposals.
Proposed charter amendments: conditional implementation · Filed 27/03/2026
The following table presents total Company revenue by operating segment: For the Six Months Ended June 30, Net Revenue (dollars in thousands) 2026 2025 Dollar Change Reported Revenue Growth (1) Percentage Change from Currency Percentage Change from Acquisitions Organic Revenue Growth (1) CAG $ 2,172,288 $ 1,942,279 $ 230,009 11.8 % 1.7 % — 10.1 % United States 1,425,792 1,308,386 117,406 9.0 % — — 9.0 % International 746,496 633,893 112,603 17.8 % 5.4 % — 12.4 % Water $ 108,829 $ 96,322 $ 12,507 13.0 % 2.8 % — 10.2 % United States 56,014 49,593 6,421 12.9 % — — 12.9 % International 52,815 46,729 6,086 13.0 % 5.6 % — 7.4 % LPD $ 67,664 $ 60,358 $ 7,306 12.1 % 4.0 % — 8.2 % United States 12,992 11,555 1,437 12.4 % — — 12.4 % International 54,672 48,803 5,869 12.0 % 4.8 % — 7.2 % Other $ 8,624 $ 8,925 $ (301) (3.4 %) — — (3.4 %) Total Company $ 2,357,405 $ 2,107,884 $ 249,521 11.8 % 1.8 % — 10.0 % United States 1,498,200 1,372,730 125,470 9.1 % — — 9.1 % International 859,205 735,154 124,051 16.9 % 5.3 % — 11.6 % (1)Reported revenue growth and organic revenue growth may not recalculate due to rounding.
Six-month segment revenue: reported and organic growth · Filed 04/08/2026
Maintaining or enhancing our growth rates and profitability depends on successful execution of many elements of our strategy, including: •Developing, manufacturing, and marketing innovative new or improved and cost competitive point-of-care laboratory analyzers that drive sales of IDEXX VetLab instruments, grow our installed base of instruments, and increase demand for related recurring sales of consumable products, services, and accessories; •Developing and introducing new or improved innovative diagnostic tests and services for both our reference laboratories and point-of-care applications that provide valuable medical information to our customers and effectively differentiate our products and services from those of our competitors; •Developing and introducing new or improved innovative, data-insightful software solutions that enable our veterinary customers to improve practice management and efficiency, staff productivity, and client engagement and communications and that increase the value to our customers of our other companion animal products and services by enhancing the integration of the information and transactions of these products and services and supporting the interpretation and management of diagnostic information derived from these products and services; •Maintaining premium pricing, including by effectively implementing price increases, for our products and services through, among other things, effective communication and promotion of their value in an environment where many of our competitors promote, market, and sell lesser offerings at lower prices; •Providing our veterinary customers with the medical and business tools, information, and resources that enable them to grow their practices and increase utilization of our diagnostic products and services through increased pet visits and preventive care protocol use, enhanced practice of real-time care, and improved practice efficiency; •Achieving cost improvements in our worldwide reference laboratory network by implementing global best practices, including lean processing techniques, technological enhancements (e.g., automation and a global laboratory information management system), purchasing strategies that maximize leverage from our global scale, increasing the leverage of existing infrastructure, and consolidating testing in high volume laboratory hubs; •Achieving cost improvements in the manufacture and service of our point-of-care laboratory analyzers by employing the benefits of economies of scale in both negotiating supply contracts and leveraging manufacturing overhead, and by improving reliability of our instruments; •Continuing to expand, develop, and advance the effectiveness and productivity of our companion animal diagnostic sales, marketing, customer support, and logistics organizations in the U.S.
Strategy execution risks: innovation, premium pricing and prospective cost improvements · Filed 20/02/2026
